Takeda announced FDA approval of the New Drug Application (NDA) for Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. Mimrylo… read more.
HUTCHMED (China) announces that the New Drug Application (NDA) for fanregratinib (HMPL-453), a novel, selective, oral inhibitor targeting FGFR 1/2/3, has been granted conditional approval by the China… read more.
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation announced the FDA has approved BESREMi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), making it the… read more.
Eli Lilly and Company announced that the FDA approved Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV)… read more.
Pfizer Inc. and BioNTech SE announced that the FDA has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant… read more.
The National Institute for Health and Care Excellence (NICE) has issued nine Technology Appraisal decisions in August 2026, comprising five positive first recommendations, one updated positive recommendation, and… read more.
Gilead Sciences, Inc. announced that the EC has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for the treatment of adult patients with unresectable,… read more.
Insmed Incorporated announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Brinsupri (brensocatib 25-mg tablet), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in… read more.
Takeda announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of Orzeyful (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with… read more.
Regeneron Pharmaceuticals, Inc. announced the FDA has granted approval for Pasatru (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans… read more.
NICE(UK): Acalabrutinib plus venetoclax can be used as an option for untreated chronic lymphocytic leukaemia (CLL) in adults. It can only be used: i) without obinutuzumab, and ii)… read more.
NICE(UK): Acalabrutinib plus bendamustine and rituximab can be used, within its marketing authorisation, as an option for untreated mantle cell lymphoma in adults who are not eligible for… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
